Palvella Therapeutics
PVLA
73 hedge funds and large institutions have $102M invested in Palvella Therapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 11 increasing their positions, 29 reducing their positions, and 31 closing their positions.
24% more capital invested
Capital invested by funds: $82.2M → $102M (+$19.8M)
14% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $1.84M
0.19% less ownership
Funds ownership: 0.72% → 0.53% (-0.19%)
10% less funds holding
Funds holding: 81 → 73 (-8)
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
62% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.09M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.74M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.54M |
| 4 |
Morgan Stanley
New York
|
+$2.35M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.52M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.32M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$2.63M |
| 4 |
State Street
Boston,
Massachusetts
|
-$2.05M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.76M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
101
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$8K | -38 | Closed |
|
102
Russell Investments Group
London,
United Kingdom
| – | -$4K | -23 | Closed |
|
103
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$4K | -18 | Closed |
|
104
Group One Trading
Chicago,
Illinois
| – | -$877 | -4 | Closed |
|
PVLA Hedge Fund Activity: Q2 2021 in Review
73 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2021, worth a combined $102M — up 24% from $82.2M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of PVLA and 23 opened new positions — a net loss of 8 holders — while 29 trimmed existing stakes and 11 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $8.09M. The largest seller was BlackRock, cutting an estimated $6.52M.
- 73 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2021, down from 81 in Q1 2021.
- Funds reported $102M of Palvella Therapeutics stock for Q2 2021, up 24% quarter-over-quarter.
- 23 funds opened new Palvella Therapeutics positions in Q2 2021 and 31 closed out, a net change of -8 holders.
- The largest Palvella Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $8.09M added.
- The largest Palvella Therapeutics seller in Q2 2021 was BlackRock, an estimated $6.52M sold.
Based on aggregated 13F filings for Q2 2021.